From the Editor’s desk....
EASL LiverTree™, Richard Moreau, 234451
JHEP at a glance (September 2018)
EASL LiverTree™, Journal of Hepatology, 234452
Screening is caring: Community-based non-invasive diagnosis and treatment strategies for hepatitis C to reduce liver disease burden
EASL LiverTree™, Isabel Graupera, 234453
Beyond viral dependence: The pathological consequences of HCV-induced EGF signaling
EASL LiverTree™, Thomas Baumert, 234454
Muscle mass vs. adipose tissue to predict outcome in cirrhosis: Which matters and in which patients?
EASL LiverTree™, Francois Durand, 234455
Subclinical T cell-mediated liver transplant rejection: The jury is still out
EASL LiverTree™, James A. Hutchinson, 234456
Genetic inactivation of Nrf2 prevents clonal expansion of initiated cells in a nutritional model of rat hepatocarcinogenesis
EASL LiverTree™, Amedeo Columbano, 234465
The P2X4 purinergic receptor regulates hepatic myofibroblast activation during liver fibrogenesis
EASL LiverTree™, José Ursic Bedoya, 234466
Human liver infiltrating γδ T cells are composed of clonally expanded circulating and tissue-resident populations
EASL LiverTree™, Benjamin E. Willcox, 234467
JNK1 induces hedgehog signaling from stellate cells to accelerate liver regeneration in mice
EASL LiverTree™, Pierre-Alain Clavien, 234468
Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice
EASL LiverTree™, Gregory Gores, 234469
β-Hydroxybutyrate protects from alcohol-induced liver injury via a Hcar2-cAMP dependent pathway
EASL LiverTree™, Wajahat Mehal, 234470
Hip fracture risk in patients with alcoholic cirrhosis: A population-based study using English and Danish data
EASL LiverTree™, Harmony Otete, 234471
CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis
EASL LiverTree™, Xiaogang Du, 234472
Protective effects of heme oxygenase 1 during ischemia-reperfusion injury: Hepatocytes or non-parenchymal cells?
EASL LiverTree™, Qiang Xia, 234480
Reply to: “Protective effects of heme oxygenase 1 during ischemia-reperfusion injury: Hepatocytes or non parenchymal cells?”
EASL LiverTree™, Jerzy Kupiec-Weglinski, 234481
Imaging endpoints for non-alcoholic steatohepatitis (NASH) therapeutic trials: A growing role for multiparametric MRI?
EASL LiverTree™, Matt Kelly, 234482
Is obesity a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis?
EASL LiverTree™, Tian Yang, 234483
Reply to: “Is obesity a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis?”
EASL LiverTree™, Vinay Sundaram, 234484
From the Editor’s desk....
EASL LiverTree™, Richard Moreau, 226823
JHEP at a glance (August 2018)
EASL LiverTree™, Journal of Hepatology, 226824
More than meets the eye: Severe alcoholic hepatitis can present as acute-on-chronic liver failure
EASL LiverTree™, Gyongyi Szabo, 226825
Towards a definite mouse model of NAFLD
EASL LiverTree™, Anna Mae Diehl, 226826
Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis
EASL LiverTree™, Vijay Shah, 226827
Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B
EASL LiverTree™, Chun-Ying Wu, 226828
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection
EASL LiverTree™, Chiun Hsu, 226829
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis
EASL LiverTree™, Massimo Puoti, 226830
Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection
EASL LiverTree™, Gian Paolo Caviglia, 226831
A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease
EASL LiverTree™, ANTONIO COLECCHIA, 226832
The prognostic value of acute-on-chronic liver failure during the course of severe alcoholic hepatitis
EASL LiverTree™, Thierry Gustot, 226833
Pyruvate dehydrogenase complex and lactate dehydrogenase are targets for therapy of acute liver failure
EASL LiverTree™, NICOLA BRUNETTI PIERRI, 226834
Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma
EASL LiverTree™, Jean-Charles Nault, 226835
Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study
EASL LiverTree™, Alfredo Alberti, 226836
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
EASL LiverTree™, Jordi Bruix, 226837
Liver regeneration requires Yap1-TGFβ-dependent epithelial-mesenchymal transition in hepatocytes
EASL LiverTree™, Anna Mae Diehl, 226838
Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis
EASL LiverTree™, Peter Fickert, 226839
Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients
EASL LiverTree™, Alice M. Turner, 226840
A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer
EASL LiverTree™, Scott L. Friedman, 226841
Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis
EASL LiverTree™, Bernd Schnabl, 226842
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
EASL LiverTree™, Journal of Hepatology, 226843
EASL Recommendations on Treatment of Hepatitis C 2018
EASL LiverTree™, Journal of Hepatology, 226844
Liver – master and servant of serum proteome
EASL LiverTree™, Pavel Strnad, 226845
New trials and results in systemic treatment of HCC
EASL LiverTree™, Sandrine Faivre, 226846
Grand Rounds: Alcoholic Hepatitis
EASL LiverTree™, Ashwani Singal, 226847
Treatment of chronic hepatitis C
EASL LiverTree™, Xavier Forns, 226848
Herbal tea and liver injury – Tea extract or comedication can make a difference
EASL LiverTree™, Andreas Benesic, 226849
Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?
EASL LiverTree™, Mohamed Bouattour, 226850
Reply to: “Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?”
EASL LiverTree™, Didier Samuel, 226851
Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?
EASL LiverTree™, Rohit P. Ojha, 226852
Reply to: “Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?”
EASL LiverTree™, Peter Buggisch, 226853
Response to: Positron emission tomography/computed tomography with F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma
EASL LiverTree™, Walter Noordzij, 226854
Reply to: “Response to: Positron emission tomography/computed tomography with F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma”
EASL LiverTree™, Jean-Charles Nault, 226855
Potential limitations of irradiation stent implantation in unresectable malignant biliary obstruction
EASL LiverTree™, Hui-Chun Liu, 226856
Reply to: “Potential limitations of irradiation stent implantation in unresectable malignant biliary obstruction”
EASL LiverTree™, Gao-Jun Teng, 226857
From the Editor’s desk....
EASL LiverTree™, Richard Moreau, 226858
JHEP at a glance (July 2018)
EASL LiverTree™, Journal of Hepatology, 226859
New insights into HDV-induced innate immunity: MDA5 senses HDV replication
EASL LiverTree™, Stefan Wieland, 226860
Hepatitis E blood donor screening – More than a mere drop in the ocean?
EASL LiverTree™, Beat Muellhaupt, 226861
The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition
EASL LiverTree™, Maria-Carlota Londoño, 226862
Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis
EASL LiverTree™, Salvatore Petta, 226863
Hepatitis D virus replication is sensed by MDA5 and induces IFN-β/λ responses in hepatocytes
EASL LiverTree™, Stephan Urban, 226864
HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients
EASL LiverTree™, Dirk Westhölter, 226865
Recipient characteristics and morbidity and mortality after liver transplantation
EASL LiverTree™, Sumeet Asrani, 226866
Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice
EASL LiverTree™, Peng Chen, 226867
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma
EASL LiverTree™, Ming Zhao, 226868
Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes
EASL LiverTree™, Tae Wook Kang, 226869
Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET
EASL LiverTree™, Gen-Sheng Feng, 226870
Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma
EASL LiverTree™, Qiang Gao, 226871
Glycogen synthase kinase 3β promotes liver innate immune activation by restraining AMP-activated protein kinase activation
EASL LiverTree™, Yuan Zhai, 226872
Inhibition of microsomal prostaglandin E synthase-1 facilitates liver repair after hepatic injury in mice
EASL LiverTree™, Masataka Majima, 226873
Magnetic resonance cholangiogram patterns and clinical profiles of ketamine-related cholangiopathy in drug users
EASL LiverTree™, Wai K. Leung, 226874
SNX10 mediates alcohol-induced liver injury and steatosis by regulating the activation of chaperone-mediated autophagy
EASL LiverTree™, Xiaoyan Shen, 226875
Apoptosis of enterocytes and nitration of junctional complex proteins promote alcohol-induced gut leakiness and liver injury
EASL LiverTree™, Byoungjoon Song, 226876
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
EASL LiverTree™, Journal of Hepatology, 226877
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
EASL LiverTree™, Journal of Hepatology, 226878
The role of molecular enrichment on future therapies in hepatocellular carcinoma
EASL LiverTree™, Peter Galle, 226879
Drug-induced chronic liver injury
EASL LiverTree™, Naga Chalasani, 226880
A measure of alcohol consumption in late adolescence associated with liver disease after 39 years of follow-up is insufficient to guide alcohol safe limits
EASL LiverTree™, Gro Askgaard, 226881
Reply to: “A measure of alcohol consumption in late adolescence associated with liver disease after 39 years of follow-up is insufficient to guide alcohol safe limits”
EASL LiverTree™, Hannes Hagström, 226882
Primed for the spotlight: Transplantation for alcohol-associated liver disease
EASL LiverTree™, Gene Im, 226883
Reply to: “Primed for the spotlight: Transplantation for alcohol-associated liver disease”
EASL LiverTree™, Jay Luther, 226884
DCD consensus and futility in liver transplantation
EASL LiverTree™, Emmanouil Giorgakis, 226885
Reply to: “DCD consensus and futility in liver transplantation”
EASL LiverTree™, Paolo Muiesan, 226886
Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion
EASL LiverTree™, Alessandro Cucchetti, 226887
Reply to: “Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion”
EASL LiverTree™, Vincenzo MAZZAFERRO, 226888
Erratum to “A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction” [J Hepatol 67 (2017) 669–679]
EASL LiverTree™, Gloria Gonzalez-Aseguinolaza, 226889
Closing remarks: Chair
EASL LiverTree™, Prof. Agustín Albillos, Dr Maria Rescigno and Dr. Andrea De Gottardi, 221455
Designing clinical trials targeting the gut microbiota
EASL LiverTree™, Onno Holleboom, 218993
Drug- and xenobiotic metabolism and the gut microbiota
EASL LiverTree™, Francesca Romana Ponziani, 218992
Unmet technical and methodological needs
EASL LiverTree™, Jingyuan Fu, 218991
Screening for FDA-approved compounds that activate intestinal Farnesoid X Receptor by direct agonism or via inhibition of the Organic SoluteTransporter alpha-beta
EASL LiverTree™, Stan van de Graaf, 217865
Flagellin promotes inflammation and fibrosis in healthy human precision-cut liver slices
EASL LiverTree™, Su Suriguga, 217866
PROTECTIVE ROLE OF PHYSICAL EXERCISE ON GUT MICROBIOTA, METABOLIC STATUS AND GUT-LIVER AXIS MODULATION IN AN IN VIVO MODEL OF EARLY OBESITY AND NAFLD
EASL LiverTree™, Sara Carbajo-Pescador, 217863
Epigallocatechin 3-Gallate ameliorates lipid and liver injury profile through activation of NK cells in mice model of cholestatic liver fibrosis
EASL LiverTree™, Ahmad Salhab, 217838
PROTON PUMP INHIBITORS, BY BACTERIAL TRANSLOCATION, INCREASED THE RISK OF MINIMAL AND OVERT HEPATIC ENCEPHALOPATHY AND THEY ARE ASSOCIATED WITH HIGH MORTALITY IN CIRRHOTIC PATIENTS
EASL LiverTree™, Silvia Nardelli, 217864
Industry point of view: FXR agonists or antagonists
EASL LiverTree™, Luciano Adorini, 218987
Modulating the gut-liver axis in portal hypertension
EASL LiverTree™, Andrea De Gottardi, 218985
Gut microbiota, intestinal glutaminase and hepatic encephalopathy
EASL LiverTree™, Manuel Romero Gomez, 218984
Gut Permeability in Biliary Atresia Post-Kasai Portoenterostomy
EASL LiverTree™, Vandana Jain, 217845
Industry point of view: Impact of ingested bacteria on human gut microbiota
EASL LiverTree™, Muriel Derrien, 218981

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings